

# The EUROPA study: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery

<b>Submission date</b> 14/10/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 15/10/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/04/2018	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## Contact information

### Type(s)

Scientific

### Contact name

Prof K Fox

### Contact details

Royal Brompton National Heart & Lung Hospital

Sydney Street

London

United Kingdom

SW3 6NP

+44 (0)20 7351 8626

K.Fox@rbht.nhs.uk

## Additional identifiers

### Protocol serial number

CL3-09490-144

## Study information

### Scientific Title

Effects of perindopril on mortality/morbidity in patients with stable coronary artery disease without clinical heart failure: a double-blind, multicentre, randomised trial

**Acronym**

EUROPA

**Study objectives**

To evaluate the effect of perindopril on cardiovascular events in patients with stable coronary artery disease and without heart failure.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval was obtained before recruitment of the first participants

**Study design**

Randomised double-blind placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Coronary artery disease

**Interventions**

Perindopril 8 mg per day (4 mg for patients aged 70 or older) or placebo for approximately 4 years treatment, follow-up at 3 months, 6 months and every 6 months thereafter.

**Intervention Type**

Drug

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Perindopril

**Primary outcome(s)**

Composite endpoint of cardiovascular mortality, non-fatal myocardial infarction and cardiac arrest resuscitation, measured at 3 months, 6 months and every 6 months thereafter

**Key secondary outcome(s)**

Composite endpoints of mortality, non-fatal acute myocardial infarction, unstable angina and cardiac arrest resuscitation and individual endpoints, measured at 3 months, 6 months and every 6 months thereafter

**Completion date**

20/05/2003

## Eligibility

**Key inclusion criteria**

1. Aged 18 years or more, both genders
2. Stable documented coronary artery disease
3. Not scheduled for revascularisation

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Clinical signs of heart failure requiring treatment with an angiotensin converting enzyme (ACE) inhibitor
2. Uncontrolled treated hypertension
3. Clinically significant obstructive valvular disease
4. Hypertrophic cardiomyopathy

**Date of first enrolment**

22/10/1997

**Date of final enrolment**

20/05/2003

## Locations

**Countries of recruitment**

United Kingdom

England

Austria

Belgium

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Netherlands

Norway

Poland

Portugal

Slovakia

Spain

Sweden

Switzerland

Türkiye

**Study participating centre**

**Royal Brompton National Heart & Lung Hospital**

London

United Kingdom

SW3 6NP

**Sponsor information**

## Organisation

Institut de Recherches Internationales Servier (France)

## ROR

<https://ror.org/034e7c066>

## Funder(s)

### Funder type

Industry

### Funder Name

Institut de Recherches Internationales Servier (France)

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com/> if a Marketing Authorisation has been granted after 2014.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	efficacy results	06/09/2003		Yes	No
<a href="#">Results article</a>	risk reduction results	01/03/2015		Yes	No
<a href="#">Basic results</a>				No	No